Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Comparability of Litifilimab Delivered by 3 Devices in Healthy Participants
NCT06741657Phase 1Completed
- Sponsor
- Biogen
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of litifilimab in lupus erythematosus (SLE) (2 arms), sponsored by Biogen. Primary endpoints: Maximum Observed Concentration and Area Under the Concentration-Time Curve From Time 0 to Infinity. Started Jan 2025; status: completed.
02
Drugs
litifilimab
03
Conditions
lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06741657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741657.